Skip to main content
. Author manuscript; available in PMC: 2011 Oct 1.
Published in final edited form as: Lancet Oncol. 2010 Nov 18;11(12):1149–1159. doi: 10.1016/S1470-2045(10)70261-8

Figure 4. Antitumor Activity of Navitoclax.

Figure 4

Waterfall plot of maximal percent change in tumor size from baseline using standard criteria.(12, 13) Tumor subtypes are shown on the x-axis: DLBCL-diffuse large B-cell lymphoma; FL-follicular lymphoma; MCL-mantle cell lymphoma; CLL/SLL-chronic lymphocytic leukemia/small lymphocytic lymphoma; MZL-marginal zone lymphoma; HL-classical Hodgkin’s lymphoma; and NK/T-natural killer-T-cell lymphoma.